

10/552110

JC12 Rec'd PCT/PTC 04 OCT 2005

EXPRESS MAIL CERTIFICATE

DOCKET NO.: 20747/300 (ARDBW/P2990US).

APPLICANT: MILLAR, Robert Peter

TITLE: GONADOTROPIN RELEASING HORMONE ANALOGUES CONJUGATES
WITH STEROID HORMONES

Certificate is attached to the Information Disclosure Statement, PTO/SB/08A form
and PCT Search Report of the above-named application.


"EXPRESS MAIL" NUMBER: EV685738060US

DATE OF DEPOSIT: October 4, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal
Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated
above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Shawn A. Lockett

(Typed or printed name of person
mailing paper or fee)


(Signature of person mailing paper or
fee)

PATENT

Docket No.: 20747/300 (ARDBW/P2990US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MILLAR, Robert Peter)
)
U. S. Serial No:	To be assigned)
)
Filed:	Herewith)
)
PCT International)
Application No:	PCT/GB2004/001478)
)
Filed:	5 April 2004)
)
For :	GONADOTROPIN RELEASING)
	HORMONE ANALOGUES)
	CONJUGATES WITH STEROID)
	HORMONES)
)

INFORMATION DISCLOSURE STATEMENT

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


In compliance with 37 C.F.R. 1.56, 1.97, and 1.98, published art included in the International Search Report (copy enclosed) of the corresponding PCT application, is cited for consideration and listed on the enclosed PTO/SB/08 form. These references are relevant for the reasons given in the search report.

Because copies of references 1-8 should have been transferred by the International Searching Authority ("ISA"), duplicate copies are not enclosed herewith. Should the U.S. Patent and Trademark Office ("PTO") require copies of references 1-8 from applicants (i.e., the ISA has not provided them), the PTO should contact the undersigned representative directly.

It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

Date: October 4, 2005



Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		To Be Assigned	
				Filing Date		Herewith	
				First Named Inventor		Peter Robert Millar	
				Art Unit		To Be Assigned	
Examiner Name		To Be Assigned					
Sheet	1	of	1	Attorney Docket Number	20747/300 (ARDBW/P2990US)		

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				

FOREIGN PATENT DOCUMENTS							
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴	Kind Code ⁵ (if known)				
	1	WO-90/09799 A		09-07-1990	University of Colorado		
	2	EP 1 424 080 A		06-02-2004	Takeda Chemical Industries Ltd.		
	3	WO-2004/058269 A		07-15-2004	Loumaye Ernest		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	Azziz R. et al., "Leuprolide and Estrogen Versus Oral Contraceptive Pills for the Treatment of Hirsutism: a Prospective Randomized Study," <i>Journal of Clinical Endocrinology and Metabolism</i> , 80(12):3406-3411 (1995) (Abstract)	
	5	Irahara M. et al., "Efficacy of Every-Other-Day Administration of Conjugated Equine Estrogen and Medroxyprogesterone Acetate on Gonadotropin-Releasing Hormone Agonists Treatment in Women With Endometriosis," <i>Gynecologic and Obstetric Investigation</i> , 52:217-222 (2001) (Abstract)	
	6	Vincze B. et al., "Antitumour Effect of a Gonadotropin-Releasing-Hormone Antagonist (MI-1544) and its Conjugate on Human Breast Cancer Cells and Their Xenografts," <i>Journal of Cancer Research and Clinical Oncology, Springer International, Berlin, DE</i> , 120(10):578-584 (1994) (Abstract)	
	7	Ben-Yehudah A. et al., "Administration of L-GnRH-PE66 Efficiently Inhibits Growth of Colon Adenocarcinoma Xenografts in Nude Mice," <i>Int. J. Cancer</i> , 92:263-268 (2001) (Abstract)	
	8	Chengalvala M. V. et al., "GnRH Agonists and Antagonists in Cancer Therapy," <i>Curr. Med. Chem.-Anticancer Agents</i> , 3(6):399-410 (2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.